悦康药业：子公司YKYY029注射液获得国家药品监督管理局临床试验批准

格隆汇资讯2025-07-17

格隆汇7月17日丨悦康药业(688658.SH)公布，公司子公司北京悦康科创医药科技股份有限公司（称“悦康科创”）、杭州天龙药业有限公司（称“杭州天龙”）于近日获得国家药品监督管理局（称“NMPA”）核准签发的关于YKYY029注射液用于治疗高血压的《药物临床试验批准通知书》，公司将开展本品I期临床试验。YKYY029注射液作为一款siRNA药物，其独特之处在于偶联了公司自主研发的、具有完全自主...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2552210202?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-17 17:11","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2552210202","market":"sh","top_or_hot":-1,"title":"悦康药业：子公司YKYY029注射液获得国家药品监督管理局临床试验批准","media":"格隆汇资讯","content":"<div>\n<p>格隆汇7月17日丨悦康药业(688658.SH)公布，公司子公司北京悦康科创医药科技股份有限公司（称“悦康科创”）、杭州天龙药业有限公司（称“杭州天龙”）于近日获得国家药品监督管理局（称“NMPA”）核准签发的关于YKYY029注射液用于治疗高血压的《药物临床试验批准通知书》，公司将开展本品I期临床试验。YKYY029注射液作为一款siRNA药物，其独特之处在于偶联了公司自主研发的、具有完全自主...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507171711319545f343&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>悦康药业：子公司YKYY029注射液获得国家药品监督管理局临床试验批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n悦康药业：子公司YKYY029注射液获得国家药品监督管理局临床试验批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-17 17:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507171711319545f343&s=b><strong>格隆汇资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇7月17日丨悦康药业(688658.SH)公布，公司子公司北京悦康科创医药科技股份有限公司（称“悦康科创”）、杭州天龙药业有限公司（称“杭州天龙”）于近日获得国家药品监督管理局（称“NMPA”）核准签发的关于YKYY029注射液用于治疗高血压的《药物临床试验批准通知书》，公司将开展本品I期临床试验。YKYY029注射液作为一款siRNA药物，其独特之处在于偶联了公司自主研发的、具有完全自主...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507171711319545f343&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688658","symbol_name":"悦康药业","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507171711319545f343&s=b","article_id":"2552210202","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507171711319545f343&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2552210202","pubTimestamp":1752743465,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"格隆汇7月17日丨悦康药业公布，公司子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司于近日获得国家药品监督管理局核准签发的关于YKYY029注射液用于治疗高血压的《药物临床试验批准通知书》，公司将开展本品I期临床试验。YKYY029注射液作为一款siRNA药物，其独特之处在于偶联了公司自主研发的、具有完全自主知识产权的GalNAc递送系统。YKYY029注射液通过siRNA的干扰沉默机制，从源头靶向沉默AGTmRNA，有效阻断AGT蛋白的合成。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688658":"悦康药业","BK0239":"医药制造"},"translate_title":"Yuekang Pharmaceutical: Subsidiary YKYY029 injection obtained clinical trial approval from the State Medical Products Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688658":1},"content_text":"格隆汇7月17日丨悦康药业(688658.SH)公布，公司子公司北京悦康科创医药科技股份有限公司（称“悦康科创”）、杭州天龙药业有限公司（称“杭州天龙”）于近日获得国家药品监督管理局（称“NMPA”）核准签发的关于YKYY029注射液用于治疗高血压的《药物临床试验批准通知书》，公司将开展本品I期临床试验。YKYY029注射液作为一款siRNA药物，其独特之处在于偶联了公司自主研发的、具有完全自主知识产权的GalNAc递送系统。该系统已获得国家知识产权局发明专利授权，并同步完成了PCT国际申请，能够实现高效的肝靶向递送。YKYY029注射液通过siRNA的干扰沉默机制，从源头靶向沉默AGTmRNA，有效阻断AGT蛋白的合成。AGT蛋白作为肾素-血管紧张素-醛固酮系统（Renin-angiotensin-aldosteronesystem，RAAS）的上游蛋白，抑制其表达将从根本上抑制RAAS系统升高血压的作用，从而降低血压。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552210202","isCrawlerRequest":true}